• GE HealthCare published its 2025 annual report, highlighting disciplined execution and operational resilience amid tariff-driven disruption.
• Commercial momentum supported a record backlog, reinforcing demand for new products across portfolio.
• Innovation pipeline advanced, with new product introduction vitality rate reaching 55%.
• Product launches targeted higher-growth areas in cardiology and imaging, including new CT and MR platforms.
• Strategic focus shifted further toward AI and cloud, supported by 115 AI-enabled FDA authorizations and planned acquisition of Intelerad to expand connected imaging and SaaS.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GE HealthCare Technologies Inc. published the original content used to generate this news brief on April 10, 2026, and is solely responsible for the information contained therein.